胺三甲基环戊甲野芝麻碱 | 128600-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 胺三甲基环戊甲野芝麻碱
• 中文别名: 3-异丙基-1,5,6-三甲基-2(1H)-吡嗪酮
• 英文名称: 1,5,6-Trimethyl-3-(propan-2-yl)pyrazin-2(1H)-one
• 英文别名: 1,5,6-trimethyl-3-propan-2-ylpyrazin-2-one
• CAS: 128600-01-1
• 化学式: C₁₀H₁₆N₂O
• mdl: MFCD18811292
• 分子量: 180.25
• InChiKey: XXAWUXLLMSRGAS-UHFFFAOYSA-N

物化性质

• 沸点：
  252.0±23.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Compounds for inhibition of alpha 4 beta 7 integrin
  申请人：Gilead Sciences, Inc.

  公开号：US11224600B2

  公开（公告）日：2022-01-18

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。
• COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN
  申请人：Gilead Sciences, Inc.

  公开号：US20200155563A1

  公开（公告）日：2020-05-21

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
• QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20220119383A1

  公开（公告）日：2022-04-21

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.